BTTC 2014 Annual Meeting

The seventh annual Brain Tumor Trials Collaborative (BTTC) meeting was held on February 21, 2014 in Houston, TX.

In the seventh year, it is easy to see the expansion of the BTTC. There are currently seven clinical trials either open or in development. The BTTC is a network with the expertise and the desire to participate in state-of-the-art clinical trials investigating new treatments for malignant brain tumors. At the annual meeting, around 80 members from all over the U.S. discussed the expanding portfolio of BTTC clinical trials.

Dr. Mark Gilbert, Principal Investigator of BTTC, welcomed members to the meeting.

Clinical Trials

Dr. Jeffrey Raizer (Northwestern University) presented the BTTC09-01 clinical trial: A phase I-II trial to determine the tolerated dose level and the safety of using a combination of two medications: everolimus and sorafenib with recurrent high-grade gliomas. We continue to accrue rapidly and hope to reach accrual within six months.

Dr. Jing Wu (University of North Carolina) and Dr. Vinay Puduvalli (Ohio State University) discussed the BTTC11-02 clinical trial: A phase I/II adaptive randomized trial of bevacizumab and vorinostat in adults with recurrent glioblastoma. Accrual has been brisk and there is great enthusiasm for this study.

Dr. Andrew Norden (Dana-Farber Cancer Institute) discussed the BTTC11-01 clinical trial: A randomized, double-blind, placebo-controlled trial of lacosamide for seizure prophylaxis in patients with high-grade gliomas. This trial is a novel design and important for those affected by a brain tumor.

Dr. Morris Groves (US Oncology) continued with a discussion about the BTTC12-01 clinical trial: to learn if pazopanib when given in combination with topotecan can help to control glioblastoma. This study was recently launched in November of 2013. It is currently available at four BTTC sites, but we plan to open to all the sites in the near future.

As the meeting continued, members of BTTC presented and discussed possible upcoming studies and research concepts.

Matt Anthony, Chairman of Head for the Cure (HFTC), gave an update on the Head for the Cure Foundation and its growth and expansion.  Over the past 11 years, more than 50,000 people participated in the 5k events. He also showed the progressive increase in financial support for the BTTC – over $3.3 million raised since 2003! Last year, several new cities participated, including: Central Texas, St. Louis, Houston and Tulsa. There was a positive response from members and enthusiasm about the new sites that are in the planning stages, including: Chicago, Detroit, Omaha, Des Moines, and Seattle with a total of 15 cities in 2014!

We are truly inspired by Matt Anthony’s continuous efforts as well as all of the participants and volunteers who spend their time raising funds for BTTC. Matt Anthony presented a check for $375,000 to BTTC from 2013 events. The meeting concluded with members rejuvenated and determined to find a cure.